Constream Biotech - A Pioneer in CDR Grafting Antibody Humanization Technology

In antibody drug development, reducing immunogenicity while preserving targeting ability is a core challenge for clinical translation. Constream Biotech, with its CDR grafting antibody humanization technology, provides scientific solutions for global clients, helping to achieve breakthroughs in both safety and efficacy of antibody drugs!

Technical Advantages

Accurate Design: By accurately grafting the complementarity determining regions (CDRs) of murine/rabbit antibodies onto human antibody framework regions (FRs), the high affinity and specificity of the original antibody are largely retained, while simultaneously eliminating the risk of xenogenicity.

Intelligent Optimization: Based on structural biology and AI algorithms, key FR residues are rationally designed to enhance antibody stability and developability, avoiding the loss of activity caused by traditional humanization.

Efficiency Verification: Combining surface plasmon resonance (SPR), immunogenicity prediction software, and in vitro/in vivo functional experiments to comprehensively evaluate the binding activity and clinical safety of humanized antibodies.

Service Highlights

Full Cycle Coverage: Providing one-stop humanization development services, from sequence analysis, CDR grafting, affinity recovery to stable cell line construction.

High Success Rate: Based on experience with over 50 successful cases, immunogenicity reduction of humanized antibodies >90%, affinity retention rate >85%.

Flexible Adaptability: Supports various forms such as monoclonal antibodies, bispecific antibodies, scFv and nanobodies, adaptable to diverse fields such as tumors, autoimmune diseases, and infectious diseases.

Specific Content

Humanization of antibodies from mice or other species using CDR grafting.

Taking mice as an example, this method mainly includes the following steps:

Analysis of murine antibody sequences and confirmation of CDR sequences: Overall analysis of murine antibody sequences, determination of CDR regions, and prediction of potential post-translational modification sites.

Selection of human framework regions: Confirmation of suitable human framework regions based on homology comparison results.

Back mutation sites: Confirmation of back mutation sites based on the binding of antibody light and heavy chains and the impact on CDR loops.

Gene synthesis and construction of eukaryotic expression plasmids: Reverse translation of the humanized antibody amino acid sequence into bases, codon optimization, and construction into eukaryotic expression plasmids.

Expression and purification: Transient transfection into CHO or HEK293 for expression and purification.

Affinity determination: Evaluation of the affinity of the humanized antibody after grafting using Biacore.

The advantage of the CDR grafting method is that it maintains the antigen-binding ability of the original murine antibody while reducing the immunogenicity and potential adverse reactions of the murine antibody.

Service Process

Service Cases

Whether it's early antibody humanization or preclinical candidate molecule optimization, Constream Biotech, based on innovative technology and rich experience, empowers the entire leap of antibody drugs from the laboratory to the market. Consult now and start a new chapter in the development of low-immunogenic, high-efficacy antibodies!